Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02326441 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies
A Phase 1 study, sponsored by Athenex.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT02326441 is a Phase 1 study that has completed, run by Athenex. The registered enrollment target is 29 participants.
The verdict
NCT02326441, a Phase 1 study, has completed, sponsored by Athenex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of the study drug KX2-361 and to determine how much of the study drug enters the bloodstream, in patients with advanced malignancies that have not responded to conventional therapies.
Interventions
- DRUG KX2-361
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-05-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02326441
The ClinicalTrials.gov registry entry for NCT02326441 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Athenex, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KX2-361 is the first listed.
NCT02326441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02326441 about?
NCT02326441 is a clinical study titled "Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies". The purpose of this study is to determine the safety and tolerability of the study drug KX2-361 and to determine how much of the study drug enters the bloodstream, in patients with advanced malignancies that have not responded to conventional therapies.
What is the current status of trial NCT02326441?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2014-12. Estimated completion is 2018-05-23.
What interventions are being tested in trial NCT02326441?
The interventions under investigation include: KX2-361 (DRUG).
Who is sponsoring clinical trial NCT02326441?
This trial is sponsored by Athenex, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.